Key facts
- It has raised $1.4M; the latest was Angel (individual) ($810K) in Jul 2025.
- Notable investors include MassChallenge, Nashville Entrepreneur Center, LifeX Ventures, MedTech Accelerator.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Toby (Decision/Risk Analysis)
- ·The full record, as it builds
Funding rounds
No funding rounds for Toby (Decision/Risk Analysis) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Toby (Decision/Risk Analysis)
Provider of a diagnostic testing platform intended to enable non-invasive cancer screening through urine analysis. The company offers spectroscopy-based detection and AI-driven analysis of volatile organic compounds, enabling healthcare providers and individuals to identify cancer indicators through simple and accessible testing methods.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2023
- Employees
- 6
- Website
- toby.health/
- Ownership
- Privately Held (backing)
Toby (Decision/Risk Analysis) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Toby (Decision/Risk Analysis) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Toby (Decision/Risk Analysis) in its N-PORT filings yet. We sweep new filings monthly.